Adenocarcinoma of Lung Clinical Trials

39 clinical trials for Adenocarcinoma of Lung across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma — RECRUITING · PHASE2
• Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer — RECRUITING
• RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial — RECRUITING · PHASE2
• APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch — RECRUITING
• Bioimpedance Analysis in Perioperative Assessment in Thoracic Surgery — ACTIVE_NOT_RECRUITING · NA
• Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients — COMPLETED
• Deep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT — NOT_YET_RECRUITING
• A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• CISH Inactivated TILs in the Treatment of NSCLC — WITHDRAWN · PHASE1
• Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors — TERMINATED · PHASE1
• Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) — COMPLETED · PHASE2
• Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs — COMPLETED
• NM32-2668 in Adult Patients With Selected Advanced Solid Tumors — TERMINATED · PHASE1
• To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer — COMPLETED · PHASE3
• An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung — TERMINATED · PHASE1
• Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules — OTHER
• Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib — COMPLETED · PHASE1
• Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter — OTHER
• LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) — TERMINATED · PHASE2
• HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008) — COMPLETED
• Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011) — COMPLETED
• Prognostic Value of Lung Cancer MicroAnatomy in 3D — OTHER
• Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study — OTHER
• Comparison of Robotic Arm-assisted PET/CT-guided Lung Biopsy With PET Fused CT- Fluoroscopy-guided Lung Biopsy — COMPLETED
• ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas — OTHER · PHASE1
• Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer — OTHER · PHASE1
• Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis — OTHER
• Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma — WITHDRAWN · PHASE1
• An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors — COMPLETED
• The Detection of EGFR Mutations in Liquid Based Cytology Samples — COMPLETED
• Vaccine Treatment for Advanced Non-Small Cell Lung Cancer — COMPLETED · PHASE1
• Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China — COMPLETED
• SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma — COMPLETED · PHASE1
• The Tracking Molecular Evolution for NSCLC (T-MENC) Study — OTHER
• Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma — OTHER
• ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC — OTHER
• Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma — OTHER · PHASE4
• The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR — ACTIVE_NOT_RECRUITING · PHASE2

Refine this search